Refugee Health TA

Providing Technical Assistance and Support on Health and Mental Health of Refugees Resettled in the U.S.

  • Home
  • About
Webinars

Main menu

Skip to primary content
Skip to secondary content
  • Refugee Basics
    • Overview
    • Refugee Resettlement
    • Refugee Health Profiles
  • Access to Care
    • Overview
    • Affordable Care Act
    • Eligibility for Benefits and Services
    • Language Access
      • Interpreters vs. Translators
      • Interpreter Best Practices
      • Preparing for a Remote Interpreted Session
      • Translated Health Education Materials
      • FAQs
  • Physical and Mental Health
    • Health Assessment
      • Overseas Medical Exam
      • Screening Guidelines
    • Health Conditions
      • Chronic Conditions
      • Infectious Diseases
      • Women’s Health
    • Mental Health
      • Adult Mental Health
      • Suicide
      • Youth and Mental Health
    • Prevention and Wellness
      • Acculturation and Health
      • Oral Health
  • Community Dialogue
  • Refugee Health Updates
    • News
    • Resources
    • Trainings and Events
    • Funding Opportunities
    • In the Literature
Home > RHTAC Updates > CDC Guidelines for the Use and Safety Monitoring of Situro for the Treatment of MDR-TB

Post navigation

CDC Guidelines for the Use and Safety Monitoring of Situro for the Treatment of MDR-TB

In the Literature: Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis. (2013) Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep. 62(rr09);1-12.

  • About RHTAC
  • Join Our Mailing List
  • Newsletter Archive

© Copyright 2022 JSI